PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

MD Anderson research highlights for February 21, 2024

Featuring insights into AML treatments, translational models for drug development, a novel role for p53, and therapeutic targets for breast cancer and multiple myeloma

2024-02-21
(Press-News.org) HOUSTON ― The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.

Recent developments at MD Anderson offer insights into drug-drug interactions for patients with acute myeloid leukemia (AML) and myelodysplastic syndromes; patient-derived xenograft models as a viable translational research tool in early-phase clinical trials; a novel gene expression signature to stratify patients with bladder cancer; a potential therapeutic target to overcome treatment resistance in multiple myeloma; a role for mutant p53 in protecting against ferroptosis in triple-negative breast cancer; and diet modifications to improve treatment outcomes in FLT3-mutated AML.

IDH1 inhibitor lowers antifungal medication levels in patients with AML and MDS
Patients with IDH1-mutated relapsed/refractory acute myeloid leukemia (AML) usually are treated with the IDH1 inhibitor ivosidenib. However, patients with AML and myelodysplastic syndromes (MDS) are at increased risk of fungal infections and are frequently given triazole antifungal medications, such as posaconazole and voriconazole. To study possible drug-drug interactions, researchers led by Caitlin Rausch, Pharm.D., and Ashley Dinh, Pharm.D., evaluated serum triazole levels in 78 samples from 31 patients receiving ivosidenib-containing therapy in combination with posaconazole and voriconazole. They discovered median triazole levels were significantly reduced during ivosidenib treatment compared to off-treatment samples. Based on the findings, the researchers recommend therapeutic drug monitoring for all patients receiving a triazole antifungal with ivosidenib. They further suggest voriconazole should be avoided, if possible, with empiric high-dose posaconazole as a potential alternative to overcome this drug-drug interaction. Learn more in Cancer. 

Co-clinical trial shows potential of PDX models in early-phase clinical trials
Patient derived xenograft (PDX) models – which utilize tissues or cells from patients for in vivo tumor studies – are used to study antitumor activity and mechanisms of intrinsic and acquired resistance, but it is unclear how well they translate to clinical responses. To address this, researchers led by Funda Meric-Bernstam, M.D., developed PDX models in a co-clinical trial to compare against patient responses with the bispecific HER-2 targeted antibody zanidatamab. Of 36 tumors implanted, the researchers established 19 models from 17 patients with a broad range of HER2-expressing cancers. In vivo testing showed the PDXs accurately reflected the tumor characteristics and antitumor activity of their matched patients in seven of eight co-clinical models. Additionally, the researchers identified amplification of MET and MYC genes as a potential mechanism of zanidatamab resistance, showing that MET inhibitors enhanced zanidatamab both in vitro and in vivo. This study provides evidence that PDXs established from biopsies in clinical trials are a powerful translational research tool, providing further insights for developing therapeutic strategies. Learn more in Cancer Discovery.

Study identifies potential therapeutic target for subset of patients with bladder cancer
Many patients with metastatic bladder cancer have inactivated SMARCB1, which is normally involved in DNA remodeling. The loss of SMARCB1 activates the STAT3 inflammation pathway and is a well-known biomarker of aggressive renal medullary carcinoma, suggesting that these events drive tumor growth and progression. To provide further insights, researchers led by Pavlos Msaouel, M.D., Ph.D., used lab models of bladder cancer without SMARCB1. SMARCB1 deficiency led to increased STAT3 activation as well as increased tumor growth and metastasis. The researchers saw increased STAT3 activation in patients with bladder cancer and showed that treatment with a STAT3 inhibitor reduced tumor growth and metastasis in vivo, highlighting its therapeutic potential. The team also developed a novel gene expression signature to help identify SMARCB1-deficient patients most likely to benefit from STAT3 inhibitors, and they suggest it merits further clinical evaluation in this subset of patients. Learn more in Nature Communications. 

Scientists discover potential therapeutic target to overcome treatment resistance in multiple myeloma
Patients with multiple myeloma, a type of blood cancer that affects the bone marrow, can develop resistance to treatments that induce DNA damage. These treatments target interleukin enhancer binding factor 2 (ILF2), a key regulator of the DNA damage response. ILF2 is overexpressed in 70% of patients with multiple myeloma who develop treatment resistance, leading Simona Colla, Ph.D., and colleagues to further examine this pathway. They showed that cancer cells rewire their metabolism in response to DNA damage. The researchers then used CRISPR/Cas screening to identify the mitochondrial DNA repair protein DNA2 as the main driver of cancer cell survival following treatment. These preclinical results highlight DNA2 as a potential therapeutic target meriting further evaluation for overcoming treatment resistance in patients with multiple myeloma and possibly other cancers. Learn more in Nature Communications.

Mutant p53 protects against ferroptosis in triple-negative breast cancer
The TP53 tumor suppressor gene, often mutated in cancer, is an early mutation in most patients with triple-negative breast cancer (TNBC). The exact role of mutant p53 in tumor maintenance is unknown, as studies typically either express mutant p53 in all cells or remove mutant p53 in both tumor cells and the tumor microenvironment. To provide further molecular insights, researchers led by Guillermina “Gigi” Lozano, Ph.D., generated TNBC models with mutations at two specific hotspots in the TP53 gene. They engineered these models so that mutant TP53 expression could be turned on or off specifically in tumor cells, maintaining wild-type p53 in the tumor microenvironment. Turning off these hotspots triggered ferroptosis – a type of cell death dependent on iron – in vivo. Using single-cell transcriptomics, the researchers uncovered two enzymes through which mutant p53 protects against ferroptosis, highlighting specific potential targets meriting further evaluation for these patients. Learn more in Science Advances.

Diet modifications improve treatment response in models of FLT3-mutated AML
Patients with FLT3-mutated acute myeloid leukemia (AML) usually have a poor prognosis, underscoring a need to improve treatment outcomes. Studies have shown that a poor diet can lead to more aggressive tumors in other cancers, but none have examined if healthy diets can improve outcomes in FLT3-mutant AML. Researchers led by Joya Chandra, Ph.D., examined the impact of diet modification in preclinical models of FLT3-mutated AML treated with anthracycline. The treatment was more effective with a low-fat and/or low-sugar diet. Time-restricted feeding (TRF) within a 12-hour window also slowed leukemia growth compared to unrestricted access to food. Additionally, TRF and a low-sugar diet increased the expression of circadian protein BMAL1, which induced cell death. These accessible behavioral modifications slowed progression of FLT3-mutated AML growth in vivo, meriting further evaluation for this patient population. The study highlights BMAL1 as a potential therapeutic target and underscores the importance of considering diet modifications as potential options to improve treatment outcomes. Learn more in Cancer Medicine.  

Awards and honors

Valerae Lewis, M.D., chair of Orthopaedic Oncology, was appointed chair of the American Academy of Orthopaedic Surgeons’ (AAOS) Membership Council. In case you missed it
Read below to catch up on recent MD Anderson press releases.

Immunotherapy before surgery leads to promising long-term survival in sarcoma patients Biomarker-directed combination effective in immunotherapy-resistant lung cancer MD Anderson and C-Biomex sign collaborative research agreement to co-develop CBT-001 radioligand therapy in the MD Anderson Newsroom.

- 30 -

END



ELSE PRESS RELEASES FROM THIS DATE:

Engineers use AI to wrangle fusion power for the grid

Engineers use AI to wrangle fusion power for the grid
2024-02-21
In the blink of an eye, the unruly, superheated plasma that drives a fusion reaction can lose its stability and escape the strong magnetic fields confining it within the donut-shaped fusion reactor. These getaways frequently spell the end of the reaction, posing a core challenge to developing fusion as a non-polluting, virtually limitless energy source. But a Princeton-led team composed of engineers, physicists, and data scientists from the University and the Princeton Plasma Physics Laboratory (PPPL) have harnessed ...

UChicago scientists invent ultra-thin, minimally-invasive pacemaker controlled by light

2024-02-21
Sometimes our bodies need a boost. Millions of Americans rely on pacemakers—small devices that regulate the electrical impulses of the heart in order to keep it beating smoothly. But to reduce complications, researchers would like to make these devices even smaller and less intrusive. A team of researchers with the University of Chicago has developed a wireless device, powered by light, that can be implanted to regulate cardiovascular or neural activity in the body. The featherlight membranes, ...

Accelerometer-measured physical activity, sedentary time, and heart failure risk in older women

2024-02-21
About The Study: The results of this study of 5,951 women ages 63 to 99 suggest that promoting regular physical activity and minimal sedentary time may be prudent for primary prevention of heart failure and its subtype with preserved ejection fraction for which treatment is limited.  Authors: Michael J. LaMonte, Ph.D., M.P.H., of the University at Buffalo—SUNY, is the corresponding author. To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/  (doi:10.1001/jamacardio.2023.5692) Editor’s Note: Please see the article for additional information, including other ...

Lifetime suicide attempts in otherwise psychiatrically healthy individuals

2024-02-21
About The Study: In this study using data from 1,948 U.S. adults with lifetime suicide attempts from a nationally representative population-based survey, an estimated 19.6% reported not having met criteria for any psychiatric disorders prior to their first attempt. This finding challenges clinical notions of who is at risk for suicidal behavior and raises questions about the safety of limiting suicide risk screening to psychiatric populations.  Authors: Maria A. Oquendo, M.D., Ph.D., of the University of Pennsylvania in Philadelphia, is the corresponding author. To access the embargoed study: Visit our For The Media ...

Acupuncture for combat-related posttraumatic stress disorder

2024-02-21
About The Study: The acupuncture intervention used in this randomized clinical trial including 93 participants was clinically efficacious and favorably affected the psychobiology of posttraumatic stress disorder (PTSD) in combat veterans. These data build on extant literature and suggest that clinical implementation of acupuncture for PTSD, along with further research about comparative efficacy, durability, and mechanisms of effects, is warranted.  Authors: Michael Hollifield, M.D., of the Tibor Rubin VA Medical Center in Long Beach, California, is the corresponding author. To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/ (10.1001/jamapsychiatry.2023.5651) Editor’s ...

Study finds high number of persistent COVID-19 infections in the general population

2024-02-21
New study finds that persistent COVID-19 infections are surprisingly common, with around one to three in every 100 infections lasting a month or longer. Some persistent infections had a high number of mutations, suggesting they could act as reservoirs to seed new variants of concern. People with persistent infections lasting for 30 days or longer were 55% more likely to report having Long Covid than people with more typical infections. Reinfections with the same variant were rare. A new study led by the University of Oxford has ...

Researchers reveal mechanism of drug reactivating tumor suppressors

Researchers reveal mechanism of drug reactivating tumor suppressors
2024-02-21
Researchers have revealed the mechanism of a drug shown to be effective in treating certain types of cancer, which targets a protein modification silencing the expression of multiple tumor suppressor genes. They also demonstrated in clinical trials the efficacy of the drug in reducing tumor growth in blood cancer. The findings could lead to longer-term treatments for the disease and therapies for other types of cancer with similar underlying causes. A team of researchers from the University of Tokyo and their collaborators focused on therapies targeting H3K27me3, a modification on a DNA-packaging histone protein, which plays a large role in regulating ...

UNC Lineberger named as a national research hub for NIH cancer screening study

UNC Lineberger named as a national research hub for NIH cancer screening study
2024-02-21
CHAPEL HILL, NC – UNC Lineberger Comprehensive Cancer Center has been selected as one of nine national research sites for the National Cancer Institute’s (NCI), part of the National Institutes of Health, newly launched Cancer Screening Research Network (CSRN), which will evaluate promising and emerging cancer screening technologies. Supporting the Biden-Harris Administration’s Cancer Moonshot initiative, the CSRN will conduct large, multi-center cancer screening studies with diverse populations in a variety of healthcare settings. The studies are designed to identify ...

New study suggests target steps per day for reduced risk of heart failure

2024-02-21
BUFFALO, N.Y. – The science is clear that movement is good for our bodies as we age. But just how much physical activity is beneficial for people over 60? A new study from the University at Buffalo provides an answer, and it’s not 10,000 steps per day. In fact, the study — published Feb. 21 in JAMA Cardiology — of nearly 6,000 U.S. women aged 63-99 reports that, on average, 3,600 steps per day at a normal pace was associated with a 26% lower risk of developing heart failure. The observational study from the Women’s Health Initiative ...

NIH launches research network to evaluate emerging cancer screening technologies

2024-02-21
The National Institutes of Health (NIH) has launched a clinical trials network to evaluate emerging technologies for cancer screening. The Cancer Screening Research Network (CSRN) will support the Biden-Harris administration’s Cancer Moonshotâ„  by investigating how to identify cancers earlier, when they may be easier to treat. Eight groups have received funding from the National Cancer Institute (NCI), part of NIH, to carry out the initial activities of the network. “There are many cancers we still cannot reliably ...

LAST 30 PRESS RELEASES:

Preschool education: A key to supporting allophone children

CNIC scientists discover a key mechanism in fat cells that protects the body against energetic excess

Chemical replacement of TNT explosive more harmful to plants, study shows

Scientists reveal possible role of iron sulfides in creating life in terrestrial hot springs

Hormone therapy affects the metabolic health of transgender individuals

Survey of 12 European countries reveals the best and worst for smoke-free homes

First new treatment for asthma attacks in 50 years

Certain HRT tablets linked to increased heart disease and blood clot risk

Talking therapy and rehabilitation probably improve long covid symptoms, but effects modest

Ban medical research with links to the fossil fuel industry, say experts

Different menopausal hormone treatments pose different risks

Novel CAR T cell therapy obe-cel demonstrates high response rates in adult patients with advanced B-cell ALL

Clinical trial at Emory University reveals twice-yearly injection to be 96% effective in HIV prevention

Discovering the traits of extinct birds

Are health care disparities tied to worse outcomes for kids with MS?

For those with CTE, family history of mental illness tied to aggression in middle age

The sound of traffic increases stress and anxiety

Global food yields have grown steadily during last six decades

Children who grow up with pets or on farms may develop allergies at lower rates because their gut microbiome develops with more anaerobic commensals, per fecal analysis in small cohort study

North American Early Paleoindians almost 13,000 years ago used the bones of canids, felids, and hares to create needles in modern-day Wyoming, potentially to make the tailored fur garments which enabl

Higher levels of democracy and lower levels of corruption are associated with more doctors, independent of healthcare spending, per cross-sectional study of 134 countries

In major materials breakthrough, UVA team solves a nearly 200-year-old challenge in polymers

Wyoming research shows early North Americans made needles from fur-bearers

Preclinical tests show mRNA-based treatments effective for blinding condition

Velcro DNA helps build nanorobotic Meccano

Oceans emit sulfur and cool the climate more than previously thought

Nanorobot hand made of DNA grabs viruses for diagnostics and blocks cell entry

Rare, mysterious brain malformations in children linked to protein misfolding, study finds

Newly designed nanomaterial shows promise as antimicrobial agent

Scientists glue two proteins together, driving cancer cells to self-destruct

[Press-News.org] MD Anderson research highlights for February 21, 2024
Featuring insights into AML treatments, translational models for drug development, a novel role for p53, and therapeutic targets for breast cancer and multiple myeloma